drugset / Trial / NCT01169090
A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of a range of doses of SK-0403 in subjects with type 2 diabetes that are not adequately controlled on metformin alone.
Timeline
- Start
- 2010-07
- Primary completion
- 2011-07
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anagliptin | Small molecule | 100 mg | — |
| Subject | Anagliptin | Small molecule | 200 mg | — |
| Subject | Anagliptin | Small molecule | 400 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |